Taylor v. Gate Pharmaceuticals

639 N.W.2d 45, 248 Mich. App. 472
CourtMichigan Court of Appeals
DecidedFebruary 5, 2002
DocketDocket 217269, 217279, 217290, 217328, 227700
StatusPublished
Cited by15 cases

This text of 639 N.W.2d 45 (Taylor v. Gate Pharmaceuticals) is published on Counsel Stack Legal Research, covering Michigan Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Taylor v. Gate Pharmaceuticals, 639 N.W.2d 45, 248 Mich. App. 472 (Mich. Ct. App. 2002).

Opinion

Murphy, J.

At issue in these consolidated products liability appeals is the constitutionality of MCL 600.2946(5), which limits the liability of drug manufacturers and sellers. In Docket Nos. 217269, 217279, 217290, and 217328, defendants American Home Products Corporation, 1 Medeva Pharmaceutials, Inc., SmithKline Beecham Corporation, and Gate Pharmaceuticals appeal by leave granted an order of the Wayne Circuit Court that denied their motion for summary disposition predicated on MCL 600.2946(5). The court ruled that MCL 600.2946(5) was unconstitu *476 tional because it improperly delegated to the United States Food and Drug Administration (fda) the legislative function of determining a cause of action. 2 In Docket No. 227700, plaintiffs Judith and Kenneth Robards appeal by leave granted an order of the Washtenaw Circuit Court granting summary disposition in favor of the manufacturing defendants on the basis of MCL 600.2946(5). That court found MCL 600.2946(5) to provide an affirmative defense to liability and held that the provision was not constitutionally infirm. 3 Our review of the statutory provision at issue leads us to the conclusion that it works an unconstitutional delegation of legislative authority. Accordingly, we affirm the decision of the Wayne Circuit Court, reverse the decision of the Washtenaw Circuit Court, and remand.

Plaintiffs in these separate cases are suing the drug manufacturers and distributors of certain diet drugs. The primary drugs at issue are dexfenfluramine (commonly known as Redux) and fenfluramine and phentermine (in combination, commonly known as fen-phen). Defendants moved for summary disposition citing MCL 600.2946(5), which tort reform statute limits the liability of drug manufacturers and sellers in products liability actions if the drug at issue was approved for safety by the fda and labeled in compliance with fda standards. 4 Plaintiffs did not contest *477 the applicability of MCL 600.2946(5), nor did they argue that they had pleaded their complaints to avoid its application. Rather, plaintiffs contended that the statute was unconstitutional on various grounds.

This Court reviews de novo a trial court's ruling on a motion for summary disposition. Spiek v Dep’t of Transportation, 456 Mich 331, 337; 572 NW2d 201 (1998). The constitutionality of a statute is also reviewed de novo as a question of law. Stevenson v Reese, 239 Mich App 513, 516; 609 NW2d 195 (2000). Here, we are presented a close question: Is MCL 600.2946(5) constitutionally infirm under Const 1963, art 4, § 1 as an unlawful delegation of legislative authority? 5

The general standards applicable to claims that a statute is facially unconstitutional are well established:

Statutes are presumed to be constitutional, and courts have a duty to construe a statute as constitutional unless its unconstitutionality is clearly apparent. Caterpillar, Inc v Dep’t of Treasury, 440 Mich 400, 413; 488 NW2d 182 (1992); Mahaffey v Attorney General, 222 Mich App 325, 344; 564 NW2d 104 (1997). The party asserting the constitutional challenge has the burden of proving the law’s invalidity. In re Hamlet (After Remand), 225 Mich App 505, 521-522; 571 NW2d 750 (1997). A party challenging the facial constitutionality of a statute must establish that no circumstances exist under which it would be valid. Council of Organizations & Others For Ed About Parochiaid, Inc v Governor, 455 Mich 557, 568; 566 NW2d 208 (1997). [Stevenson, supra at 517.]

*478 The parties dispute whether MCL 600.2946(5) violates Const 1963, art 4, § 1, which states: “The legislative power of the State of Michigan is vested in a senate and a house of representatives.” Legislative power, in general, refers to the authority to make, alter, amend, and repeal laws. Harsha v Detroit, 261 Mich 586, 590; 246 NW 849 (1933). Although Michigan’s Constitution does not explicitly provide that legislative power cannot be delegated, a nondelegation doctrine has been applied through judicial interpretation. Miller v Dep’t of Treasury, 385 Mich 296, 313; 188 NW2d 795 (1971) (Brennan, J., dissenting).

Challenges premised on the theory of improper delegation are common. Thus, the framework and standards by which courts address this specific constitutional challenge are equally well established:

Challenges of unconstitutional delegation of legislative power are generally framed in terms of the adequacy of the standards fashioned by the Legislature to channel the agency’s or individual’s exercise of the delegated power. See, e.g., Osius v St Clair Shores, 344 Mich 693, 698; 75 NW2d 25 (1956). Although for many years this and other courts evaluated delegation challenges in terms of whether a legislative (policymaking) or administrative (factfinding) function was the subject of the delegation, this analysis was replaced by the “standards” test as it became apparent that the essential purpose of the delegation doctrine was to protect the public from misuses of the delegated power. The Court reasoned that if sufficient standards and safeguards directed and checked the exercise of delegated power, the Legislature could safely avail itself of the resources and expertise of agencies and individuals to assist the formulation and execution of legislative policy.
The criteria this Court has utilized in evaluating legislative standards are set forth in Dep’t of Natural Resources v Seaman, 396 Mich 299, 309; 240 NW2d 206 (1976): 1) the act must be read as a whole; 2) the act carries a presumption *479 of constitutionality; and 3) the standards must be as reasonably precise as the subject matter requires or permits. The preciseness required of the standards will depend on the complexity of the subject. Argo Oil Corp v Atwood, 274 Mich 47, 53; 264 NW 285 (1935). Additionally, due process requirements must be satisfied for the statute to pass constitutional muster. State Highway Comm v Vanderkloot, 392 Mich 159, 174; 220 NW2d 416 (1974). [Blue Cross & Blue Shield of Michigan v Governor, 422 Mich 1, 51-52; 367 NW2d 1 (1985).]

MCL 600.2946(5), as amended by 1995 PA 249, effective March 28, 1996, provides:

In a product liability action against a manufacturer or seller, a product that is a drug is not defective or unreasonably dangerous, and the manufacturer or seller is not liable, if the drug was approved for safety and efficacy by the United States food and drug administration, and the drug and its labeling were in compliance with the United States food and drug administration’s approval at the time the drug left the control of the manufacturer or seller.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Garcia v. Wyeth-Ayerst
Sixth Circuit, 2004
Julia Garcia v. Wyeth-Ayerst Laboratories
385 F.3d 961 (Sixth Circuit, 2004)
Garcia v. Wyeth-Ayerst Laboratories
265 F. Supp. 2d 825 (E.D. Michigan, 2003)
Tamara Taylor v. Gate Pharmaceuticals
Michigan Supreme Court, 2003
Judith H Robards v. Joyce E Kaferle Md
Michigan Supreme Court, 2003
Taylor v. Smithkline Beecham Corp.
658 N.W.2d 127 (Michigan Supreme Court, 2003)
Taxpayers of Michigan Against Casinos v. State
657 N.W.2d 503 (Michigan Court of Appeals, 2003)
Wayne County Board of Commissioners v. Wayne County Airport Authority
658 N.W.2d 804 (Michigan Court of Appeals, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
639 N.W.2d 45, 248 Mich. App. 472, Counsel Stack Legal Research, https://law.counselstack.com/opinion/taylor-v-gate-pharmaceuticals-michctapp-2002.